Global Oligonucleotide CDMO Market Growth (Status and Outlook) 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Oligonucleotide CDMO market size is predicted to grow from US$ 1370 million in 2025 to US$ 2847 million in 2031; it is expected to grow at a CAGR of 13.0% from 2025 to 2031.
An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.
United States market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Oligonucleotide CDMO players cover Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Oligonucleotide CDMO Industry Forecast” looks at past sales and reviews total world Oligonucleotide CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide CDMO sales for 2025 through 2031. With Oligonucleotide CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide CDMO industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
The global Oligonucleotide CDMO market size is predicted to grow from US$ 1370 million in 2025 to US$ 2847 million in 2031; it is expected to grow at a CAGR of 13.0% from 2025 to 2031.
An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.
United States market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Oligonucleotide CDMO players cover Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Oligonucleotide CDMO Industry Forecast” looks at past sales and reviews total world Oligonucleotide CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide CDMO sales for 2025 through 2031. With Oligonucleotide CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide CDMO industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
- APIs and Intermediates
- FDF
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Agilent
- ST Pharm
- Bachem
- BioSpring
- Creative Biogene
- Sylentis
- Ajinomoto Bio-Pharma
- EUROAPI
- Veliter
- PolyPeptide Group
- CordenPharma
- Thermofischer
- Bio Basic
- Genscript
- Cytiva
- ScinoPharm
- CBL
- Piramal Pharma
- CPC Scientific
- Eurogentec
- Cambrex
- WuXi STA
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oligonucleotide CDMO Market Size (2020-2031)
2.1.2 Oligonucleotide CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Oligonucleotide CDMO by Country/Region (2020, 2024 & 2031)
2.2 Oligonucleotide CDMO Segment by Type
2.2.1 APIs and Intermediates
2.2.2 FDF
2.3 Oligonucleotide CDMO Market Size by Type
2.3.1 Oligonucleotide CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Oligonucleotide CDMO Market Size Market Share by Type (2020-2025)
2.4 Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Oligonucleotide CDMO Market Size by Application
2.5.1 Oligonucleotide CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
3 OLIGONUCLEOTIDE CDMO MARKET SIZE BY PLAYER
3.1 Oligonucleotide CDMO Market Size Market Share by Player
3.1.1 Global Oligonucleotide CDMO Revenue by Player (2020-2025)
3.1.2 Global Oligonucleotide CDMO Revenue Market Share by Player (2020-2025)
3.2 Global Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE CDMO BY REGION
4.1 Oligonucleotide CDMO Market Size by Region (2020-2025)
4.2 Global Oligonucleotide CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Oligonucleotide CDMO Market Size Growth (2020-2025)
4.4 APAC Oligonucleotide CDMO Market Size Growth (2020-2025)
4.5 Europe Oligonucleotide CDMO Market Size Growth (2020-2025)
4.6 Middle East & Africa Oligonucleotide CDMO Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Oligonucleotide CDMO Market Size by Country (2020-2025)
5.2 Americas Oligonucleotide CDMO Market Size by Type (2020-2025)
5.3 Americas Oligonucleotide CDMO Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide CDMO Market Size by Region (2020-2025)
6.2 APAC Oligonucleotide CDMO Market Size by Type (2020-2025)
6.3 APAC Oligonucleotide CDMO Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oligonucleotide CDMO Market Size by Country (2020-2025)
7.2 Europe Oligonucleotide CDMO Market Size by Type (2020-2025)
7.3 Europe Oligonucleotide CDMO Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oligonucleotide CDMO by Region (2020-2025)
8.2 Middle East & Africa Oligonucleotide CDMO Market Size by Type (2020-2025)
8.3 Middle East & Africa Oligonucleotide CDMO Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL OLIGONUCLEOTIDE CDMO MARKET FORECAST
10.1 Global Oligonucleotide CDMO Forecast by Region (2026-2031)
10.1.1 Global Oligonucleotide CDMO Forecast by Region (2026-2031)
10.1.2 Americas Oligonucleotide CDMO Forecast
10.1.3 APAC Oligonucleotide CDMO Forecast
10.1.4 Europe Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Oligonucleotide CDMO Forecast
10.2 Americas Oligonucleotide CDMO Forecast by Country (2026-2031)
10.2.1 United States Market Oligonucleotide CDMO Forecast
10.2.2 Canada Market Oligonucleotide CDMO Forecast
10.2.3 Mexico Market Oligonucleotide CDMO Forecast
10.2.4 Brazil Market Oligonucleotide CDMO Forecast
10.3 APAC Oligonucleotide CDMO Forecast by Region (2026-2031)
10.3.1 China Oligonucleotide CDMO Market Forecast
10.3.2 Japan Market Oligonucleotide CDMO Forecast
10.3.3 Korea Market Oligonucleotide CDMO Forecast
10.3.4 Southeast Asia Market Oligonucleotide CDMO Forecast
10.3.5 India Market Oligonucleotide CDMO Forecast
10.3.6 Australia Market Oligonucleotide CDMO Forecast
10.4 Europe Oligonucleotide CDMO Forecast by Country (2026-2031)
10.4.1 Germany Market Oligonucleotide CDMO Forecast
10.4.2 France Market Oligonucleotide CDMO Forecast
10.4.3 UK Market Oligonucleotide CDMO Forecast
10.4.4 Italy Market Oligonucleotide CDMO Forecast
10.4.5 Russia Market Oligonucleotide CDMO Forecast
10.5 Middle East & Africa Oligonucleotide CDMO Forecast by Region (2026-2031)
10.5.1 Egypt Market Oligonucleotide CDMO Forecast
10.5.2 South Africa Market Oligonucleotide CDMO Forecast
10.5.3 Israel Market Oligonucleotide CDMO Forecast
10.5.4 Turkey Market Oligonucleotide CDMO Forecast
10.6 Global Oligonucleotide CDMO Forecast by Type (2026-2031)
10.7 Global Oligonucleotide CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Oligonucleotide CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 Agilent
11.1.1 Agilent Company Information
11.1.2 Agilent Oligonucleotide CDMO Product Offered
11.1.3 Agilent Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Agilent Main Business Overview
11.1.5 Agilent Latest Developments
11.2 ST Pharm
11.2.1 ST Pharm Company Information
11.2.2 ST Pharm Oligonucleotide CDMO Product Offered
11.2.3 ST Pharm Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 ST Pharm Main Business Overview
11.2.5 ST Pharm Latest Developments
11.3 Bachem
11.3.1 Bachem Company Information
11.3.2 Bachem Oligonucleotide CDMO Product Offered
11.3.3 Bachem Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Bachem Main Business Overview
11.3.5 Bachem Latest Developments
11.4 BioSpring
11.4.1 BioSpring Company Information
11.4.2 BioSpring Oligonucleotide CDMO Product Offered
11.4.3 BioSpring Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 BioSpring Main Business Overview
11.4.5 BioSpring Latest Developments
11.5 Creative Biogene
11.5.1 Creative Biogene Company Information
11.5.2 Creative Biogene Oligonucleotide CDMO Product Offered
11.5.3 Creative Biogene Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Creative Biogene Main Business Overview
11.5.5 Creative Biogene Latest Developments
11.6 Sylentis
11.6.1 Sylentis Company Information
11.6.2 Sylentis Oligonucleotide CDMO Product Offered
11.6.3 Sylentis Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Sylentis Main Business Overview
11.6.5 Sylentis Latest Developments
11.7 Ajinomoto Bio-Pharma
11.7.1 Ajinomoto Bio-Pharma Company Information
11.7.2 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Offered
11.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Ajinomoto Bio-Pharma Main Business Overview
11.7.5 Ajinomoto Bio-Pharma Latest Developments
11.8 EUROAPI
11.8.1 EUROAPI Company Information
11.8.2 EUROAPI Oligonucleotide CDMO Product Offered
11.8.3 EUROAPI Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 EUROAPI Main Business Overview
11.8.5 EUROAPI Latest Developments
11.9 Veliter
11.9.1 Veliter Company Information
11.9.2 Veliter Oligonucleotide CDMO Product Offered
11.9.3 Veliter Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Veliter Main Business Overview
11.9.5 Veliter Latest Developments
11.10 PolyPeptide Group
11.10.1 PolyPeptide Group Company Information
11.10.2 PolyPeptide Group Oligonucleotide CDMO Product Offered
11.10.3 PolyPeptide Group Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 PolyPeptide Group Main Business Overview
11.10.5 PolyPeptide Group Latest Developments
11.11 CordenPharma
11.11.1 CordenPharma Company Information
11.11.2 CordenPharma Oligonucleotide CDMO Product Offered
11.11.3 CordenPharma Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 CordenPharma Main Business Overview
11.11.5 CordenPharma Latest Developments
11.12 Thermofischer
11.12.1 Thermofischer Company Information
11.12.2 Thermofischer Oligonucleotide CDMO Product Offered
11.12.3 Thermofischer Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Thermofischer Main Business Overview
11.12.5 Thermofischer Latest Developments
11.13 Bio Basic
11.13.1 Bio Basic Company Information
11.13.2 Bio Basic Oligonucleotide CDMO Product Offered
11.13.3 Bio Basic Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Bio Basic Main Business Overview
11.13.5 Bio Basic Latest Developments
11.14 Genscript
11.14.1 Genscript Company Information
11.14.2 Genscript Oligonucleotide CDMO Product Offered
11.14.3 Genscript Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Genscript Main Business Overview
11.14.5 Genscript Latest Developments
11.15 Cytiva
11.15.1 Cytiva Company Information
11.15.2 Cytiva Oligonucleotide CDMO Product Offered
11.15.3 Cytiva Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Cytiva Main Business Overview
11.15.5 Cytiva Latest Developments
11.16 ScinoPharm
11.16.1 ScinoPharm Company Information
11.16.2 ScinoPharm Oligonucleotide CDMO Product Offered
11.16.3 ScinoPharm Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 ScinoPharm Main Business Overview
11.16.5 ScinoPharm Latest Developments
11.17 CBL
11.17.1 CBL Company Information
11.17.2 CBL Oligonucleotide CDMO Product Offered
11.17.3 CBL Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 CBL Main Business Overview
11.17.5 CBL Latest Developments
11.18 Piramal Pharma
11.18.1 Piramal Pharma Company Information
11.18.2 Piramal Pharma Oligonucleotide CDMO Product Offered
11.18.3 Piramal Pharma Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Piramal Pharma Main Business Overview
11.18.5 Piramal Pharma Latest Developments
11.19 CPC Scientific
11.19.1 CPC Scientific Company Information
11.19.2 CPC Scientific Oligonucleotide CDMO Product Offered
11.19.3 CPC Scientific Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 CPC Scientific Main Business Overview
11.19.5 CPC Scientific Latest Developments
11.20 Eurogentec
11.20.1 Eurogentec Company Information
11.20.2 Eurogentec Oligonucleotide CDMO Product Offered
11.20.3 Eurogentec Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Eurogentec Main Business Overview
11.20.5 Eurogentec Latest Developments
11.21 Cambrex
11.21.1 Cambrex Company Information
11.21.2 Cambrex Oligonucleotide CDMO Product Offered
11.21.3 Cambrex Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Cambrex Main Business Overview
11.21.5 Cambrex Latest Developments
11.22 WuXi STA
11.22.1 WuXi STA Company Information
11.22.2 WuXi STA Oligonucleotide CDMO Product Offered
11.22.3 WuXi STA Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 WuXi STA Main Business Overview
11.22.5 WuXi STA Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
.
Table 1. Oligonucleotide CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Oligonucleotide CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of APIs and Intermediates
Table 4. Major Players ofFDF
Table 5. Oligonucleotide CDMO Market Size CAGR byType (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 7. Global Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Table 8. Oligonucleotide CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Table 11. Global Oligonucleotide CDMO Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Oligonucleotide CDMO Revenue Market Share by Player (2020-2025)
Table 13. Oligonucleotide CDMO Key Players Head office and Products Offered
Table 14. Oligonucleotide CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Oligonucleotide CDMO Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Table 19. Global Oligonucleotide CDMO Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Oligonucleotide CDMO Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Oligonucleotide CDMO Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Oligonucleotide CDMO Market Size Market Share by Country (2020-2025)
Table 23. Americas Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 24. Americas Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Table 25. Americas Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Table 27. APAC Oligonucleotide CDMO Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Table 29. APAC Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 30. APAC Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Oligonucleotide CDMO Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Oligonucleotide CDMO Market Size Market Share by Country (2020-2025)
Table 33. Europe Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 34. Europe Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Oligonucleotide CDMO Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Oligonucleotide CDMO
Table 39. Key Market Challenges & Risks of Oligonucleotide CDMO
Table 40. Key IndustryTrends of Oligonucleotide CDMO
Table 41. Global Oligonucleotide CDMO Market SizeForecast by Region (2026-2031) & ($ millions)
Table 42. Global Oligonucleotide CDMO Market Size Market ShareForecast by Region (2026-2031)
Table 43. Global Oligonucleotide CDMO Market SizeForecast byType (2026-2031) & ($ millions)
Table 44. Global Oligonucleotide CDMO Market SizeForecast by Application (2026-2031) & ($ millions)
Table 45. Agilent Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 46. Agilent Oligonucleotide CDMO Product Offered
Table 47. Agilent Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Agilent Main Business
Table 49. Agilent Latest Developments
Table 50. ST Pharm Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 51. ST Pharm Oligonucleotide CDMO Product Offered
Table 52. ST Pharm Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. ST Pharm Main Business
Table 54. ST Pharm Latest Developments
Table 55. Bachem Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 56. Bachem Oligonucleotide CDMO Product Offered
Table 57. Bachem Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Bachem Main Business
Table 59. Bachem Latest Developments
Table 60. BioSpring Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 61. BioSpring Oligonucleotide CDMO Product Offered
Table 62. BioSpring Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. BioSpring Main Business
Table 64. BioSpring Latest Developments
Table 65. Creative Biogene Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 66. Creative Biogene Oligonucleotide CDMO Product Offered
Table 67. Creative Biogene Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Creative Biogene Main Business
Table 69. Creative Biogene Latest Developments
Table 70. Sylentis Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 71. Sylentis Oligonucleotide CDMO Product Offered
Table 72. Sylentis Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Sylentis Main Business
Table 74. Sylentis Latest Developments
Table 75. Ajinomoto Bio-Pharma Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 76. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Offered
Table 77. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Ajinomoto Bio-Pharma Main Business
Table 79. Ajinomoto Bio-Pharma Latest Developments
Table 80. EUROAPI Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 81. EUROAPI Oligonucleotide CDMO Product Offered
Table 82. EUROAPI Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. EUROAPI Main Business
Table 84. EUROAPI Latest Developments
Table 85. Veliter Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 86. Veliter Oligonucleotide CDMO Product Offered
Table 87. Veliter Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Veliter Main Business
Table 89. Veliter Latest Developments
Table 90. PolyPeptide Group Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 91. PolyPeptide Group Oligonucleotide CDMO Product Offered
Table 92. PolyPeptide Group Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. PolyPeptide Group Main Business
Table 94. PolyPeptide Group Latest Developments
Table 95. CordenPharma Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 96. CordenPharma Oligonucleotide CDMO Product Offered
Table 97. CordenPharma Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. CordenPharma Main Business
Table 99. CordenPharma Latest Developments
Table 100.Thermofischer Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 101.Thermofischer Oligonucleotide CDMO Product Offered
Table 102.Thermofischer Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 103.Thermofischer Main Business
Table 104.Thermofischer Latest Developments
Table 105. Bio Basic Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 106. Bio Basic Oligonucleotide CDMO Product Offered
Table 107. Bio Basic Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 108. Bio Basic Main Business
Table 109. Bio Basic Latest Developments
Table 110. Genscript Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 111. Genscript Oligonucleotide CDMO Product Offered
Table 112. Genscript Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 113. Genscript Main Business
Table 114. Genscript Latest Developments
Table 115. Cytiva Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 116. Cytiva Oligonucleotide CDMO Product Offered
Table 117. Cytiva Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 118. Cytiva Main Business
Table 119. Cytiva Latest Developments
Table 120. ScinoPharm Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 121. ScinoPharm Oligonucleotide CDMO Product Offered
Table 122. ScinoPharm Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 123. ScinoPharm Main Business
Table 124. ScinoPharm Latest Developments
Table 125. CBL Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 126. CBL Oligonucleotide CDMO Product Offered
Table 127. CBL Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 128. CBL Main Business
Table 129. CBL Latest Developments
Table 130. Piramal Pharma Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 131. Piramal Pharma Oligonucleotide CDMO Product Offered
Table 132. Piramal Pharma Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 133. Piramal Pharma Main Business
Table 134. Piramal Pharma Latest Developments
Table 135. CPC Scientific Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 136. CPC Scientific Oligonucleotide CDMO Product Offered
Table 137. CPC Scientific Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 138. CPC Scientific Main Business
Table 139. CPC Scientific Latest Developments
Table 140. Eurogentec Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 141. Eurogentec Oligonucleotide CDMO Product Offered
Table 142. Eurogentec Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 143. Eurogentec Main Business
Table 144. Eurogentec Latest Developments
Table 145. Cambrex Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 146. Cambrex Oligonucleotide CDMO Product Offered
Table 147. Cambrex Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 148. Cambrex Main Business
Table 149. Cambrex Latest Developments
Table 150. WuXi STA Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 151. WuXi STA Oligonucleotide CDMO Product Offered
Table 152. WuXi STA Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 153. WuXi STA Main Business
Table 154. WuXi STA Latest Developments
LIST OFFIGURES
Figure 1. Oligonucleotide CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide CDMO Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Oligonucleotide CDMO Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Oligonucleotide CDMO Sales Market Share by Country/Region (2024)
Figure 8. Oligonucleotide CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Oligonucleotide CDMO Market Size Market Share byType in 2024
Figure 10. Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies
Figure 11. Global Oligonucleotide CDMO Market: Pharmaceutical and Biotechnology Companies (2020-2025) & ($ millions)
Figure 12. Oligonucleotide CDMO in Research Institutes
Figure 13. Global Oligonucleotide CDMO Market: Research Institutes (2020-2025) & ($ millions)
Figure 14. Oligonucleotide CDMO in Others
Figure 15. Global Oligonucleotide CDMO Market: Others (2020-2025) & ($ millions)
Figure 16. Global Oligonucleotide CDMO Market Size Market Share by Application in 2024
Figure 17. Global Oligonucleotide CDMO Revenue Market Share by Player in 2024
Figure 18. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Figure 19. Americas Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 20. APAC Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 21. Europe Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 23. Americas Oligonucleotide CDMO Value Market Share by Country in 2024
Figure 24. United States Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Oligonucleotide CDMO Market Size Market Share by Region in 2024
Figure 29. APAC Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Figure 30. APAC Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Figure 31. China Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 35. India Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Oligonucleotide CDMO Market Size Market Share by Country in 2024
Figure 38. Europe Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Figure 39. Europe Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Figure 40. Germany Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 41.France Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Figure 47. Middle East & Africa Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 51.Turkey Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 54. APAC Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 55. Europe Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 57. United States Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 58. Canada Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 59. Mexico Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 60. Brazil Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 61. China Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 62. Japan Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 63. Korea Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 65. India Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 66. Australia Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 67. Germany Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 68.France Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 69. UK Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 70. Italy Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 71. Russia Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 72. Egypt Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 73. South Africa Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 74. Israel Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 75.Turkey Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 76. Global Oligonucleotide CDMO Market Size Market ShareForecast byType (2026-2031)
Figure 77. Global Oligonucleotide CDMO Market Size Market ShareForecast by Application (2026-2031)
Figure 78. GCC Countries Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oligonucleotide CDMO Market Size (2020-2031)
2.1.2 Oligonucleotide CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Oligonucleotide CDMO by Country/Region (2020, 2024 & 2031)
2.2 Oligonucleotide CDMO Segment by Type
2.2.1 APIs and Intermediates
2.2.2 FDF
2.3 Oligonucleotide CDMO Market Size by Type
2.3.1 Oligonucleotide CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Oligonucleotide CDMO Market Size Market Share by Type (2020-2025)
2.4 Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Oligonucleotide CDMO Market Size by Application
2.5.1 Oligonucleotide CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
3 OLIGONUCLEOTIDE CDMO MARKET SIZE BY PLAYER
3.1 Oligonucleotide CDMO Market Size Market Share by Player
3.1.1 Global Oligonucleotide CDMO Revenue by Player (2020-2025)
3.1.2 Global Oligonucleotide CDMO Revenue Market Share by Player (2020-2025)
3.2 Global Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE CDMO BY REGION
4.1 Oligonucleotide CDMO Market Size by Region (2020-2025)
4.2 Global Oligonucleotide CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Oligonucleotide CDMO Market Size Growth (2020-2025)
4.4 APAC Oligonucleotide CDMO Market Size Growth (2020-2025)
4.5 Europe Oligonucleotide CDMO Market Size Growth (2020-2025)
4.6 Middle East & Africa Oligonucleotide CDMO Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Oligonucleotide CDMO Market Size by Country (2020-2025)
5.2 Americas Oligonucleotide CDMO Market Size by Type (2020-2025)
5.3 Americas Oligonucleotide CDMO Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide CDMO Market Size by Region (2020-2025)
6.2 APAC Oligonucleotide CDMO Market Size by Type (2020-2025)
6.3 APAC Oligonucleotide CDMO Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oligonucleotide CDMO Market Size by Country (2020-2025)
7.2 Europe Oligonucleotide CDMO Market Size by Type (2020-2025)
7.3 Europe Oligonucleotide CDMO Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oligonucleotide CDMO by Region (2020-2025)
8.2 Middle East & Africa Oligonucleotide CDMO Market Size by Type (2020-2025)
8.3 Middle East & Africa Oligonucleotide CDMO Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL OLIGONUCLEOTIDE CDMO MARKET FORECAST
10.1 Global Oligonucleotide CDMO Forecast by Region (2026-2031)
10.1.1 Global Oligonucleotide CDMO Forecast by Region (2026-2031)
10.1.2 Americas Oligonucleotide CDMO Forecast
10.1.3 APAC Oligonucleotide CDMO Forecast
10.1.4 Europe Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Oligonucleotide CDMO Forecast
10.2 Americas Oligonucleotide CDMO Forecast by Country (2026-2031)
10.2.1 United States Market Oligonucleotide CDMO Forecast
10.2.2 Canada Market Oligonucleotide CDMO Forecast
10.2.3 Mexico Market Oligonucleotide CDMO Forecast
10.2.4 Brazil Market Oligonucleotide CDMO Forecast
10.3 APAC Oligonucleotide CDMO Forecast by Region (2026-2031)
10.3.1 China Oligonucleotide CDMO Market Forecast
10.3.2 Japan Market Oligonucleotide CDMO Forecast
10.3.3 Korea Market Oligonucleotide CDMO Forecast
10.3.4 Southeast Asia Market Oligonucleotide CDMO Forecast
10.3.5 India Market Oligonucleotide CDMO Forecast
10.3.6 Australia Market Oligonucleotide CDMO Forecast
10.4 Europe Oligonucleotide CDMO Forecast by Country (2026-2031)
10.4.1 Germany Market Oligonucleotide CDMO Forecast
10.4.2 France Market Oligonucleotide CDMO Forecast
10.4.3 UK Market Oligonucleotide CDMO Forecast
10.4.4 Italy Market Oligonucleotide CDMO Forecast
10.4.5 Russia Market Oligonucleotide CDMO Forecast
10.5 Middle East & Africa Oligonucleotide CDMO Forecast by Region (2026-2031)
10.5.1 Egypt Market Oligonucleotide CDMO Forecast
10.5.2 South Africa Market Oligonucleotide CDMO Forecast
10.5.3 Israel Market Oligonucleotide CDMO Forecast
10.5.4 Turkey Market Oligonucleotide CDMO Forecast
10.6 Global Oligonucleotide CDMO Forecast by Type (2026-2031)
10.7 Global Oligonucleotide CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Oligonucleotide CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 Agilent
11.1.1 Agilent Company Information
11.1.2 Agilent Oligonucleotide CDMO Product Offered
11.1.3 Agilent Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Agilent Main Business Overview
11.1.5 Agilent Latest Developments
11.2 ST Pharm
11.2.1 ST Pharm Company Information
11.2.2 ST Pharm Oligonucleotide CDMO Product Offered
11.2.3 ST Pharm Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 ST Pharm Main Business Overview
11.2.5 ST Pharm Latest Developments
11.3 Bachem
11.3.1 Bachem Company Information
11.3.2 Bachem Oligonucleotide CDMO Product Offered
11.3.3 Bachem Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Bachem Main Business Overview
11.3.5 Bachem Latest Developments
11.4 BioSpring
11.4.1 BioSpring Company Information
11.4.2 BioSpring Oligonucleotide CDMO Product Offered
11.4.3 BioSpring Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 BioSpring Main Business Overview
11.4.5 BioSpring Latest Developments
11.5 Creative Biogene
11.5.1 Creative Biogene Company Information
11.5.2 Creative Biogene Oligonucleotide CDMO Product Offered
11.5.3 Creative Biogene Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Creative Biogene Main Business Overview
11.5.5 Creative Biogene Latest Developments
11.6 Sylentis
11.6.1 Sylentis Company Information
11.6.2 Sylentis Oligonucleotide CDMO Product Offered
11.6.3 Sylentis Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Sylentis Main Business Overview
11.6.5 Sylentis Latest Developments
11.7 Ajinomoto Bio-Pharma
11.7.1 Ajinomoto Bio-Pharma Company Information
11.7.2 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Offered
11.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Ajinomoto Bio-Pharma Main Business Overview
11.7.5 Ajinomoto Bio-Pharma Latest Developments
11.8 EUROAPI
11.8.1 EUROAPI Company Information
11.8.2 EUROAPI Oligonucleotide CDMO Product Offered
11.8.3 EUROAPI Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 EUROAPI Main Business Overview
11.8.5 EUROAPI Latest Developments
11.9 Veliter
11.9.1 Veliter Company Information
11.9.2 Veliter Oligonucleotide CDMO Product Offered
11.9.3 Veliter Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Veliter Main Business Overview
11.9.5 Veliter Latest Developments
11.10 PolyPeptide Group
11.10.1 PolyPeptide Group Company Information
11.10.2 PolyPeptide Group Oligonucleotide CDMO Product Offered
11.10.3 PolyPeptide Group Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 PolyPeptide Group Main Business Overview
11.10.5 PolyPeptide Group Latest Developments
11.11 CordenPharma
11.11.1 CordenPharma Company Information
11.11.2 CordenPharma Oligonucleotide CDMO Product Offered
11.11.3 CordenPharma Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 CordenPharma Main Business Overview
11.11.5 CordenPharma Latest Developments
11.12 Thermofischer
11.12.1 Thermofischer Company Information
11.12.2 Thermofischer Oligonucleotide CDMO Product Offered
11.12.3 Thermofischer Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Thermofischer Main Business Overview
11.12.5 Thermofischer Latest Developments
11.13 Bio Basic
11.13.1 Bio Basic Company Information
11.13.2 Bio Basic Oligonucleotide CDMO Product Offered
11.13.3 Bio Basic Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Bio Basic Main Business Overview
11.13.5 Bio Basic Latest Developments
11.14 Genscript
11.14.1 Genscript Company Information
11.14.2 Genscript Oligonucleotide CDMO Product Offered
11.14.3 Genscript Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Genscript Main Business Overview
11.14.5 Genscript Latest Developments
11.15 Cytiva
11.15.1 Cytiva Company Information
11.15.2 Cytiva Oligonucleotide CDMO Product Offered
11.15.3 Cytiva Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Cytiva Main Business Overview
11.15.5 Cytiva Latest Developments
11.16 ScinoPharm
11.16.1 ScinoPharm Company Information
11.16.2 ScinoPharm Oligonucleotide CDMO Product Offered
11.16.3 ScinoPharm Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 ScinoPharm Main Business Overview
11.16.5 ScinoPharm Latest Developments
11.17 CBL
11.17.1 CBL Company Information
11.17.2 CBL Oligonucleotide CDMO Product Offered
11.17.3 CBL Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 CBL Main Business Overview
11.17.5 CBL Latest Developments
11.18 Piramal Pharma
11.18.1 Piramal Pharma Company Information
11.18.2 Piramal Pharma Oligonucleotide CDMO Product Offered
11.18.3 Piramal Pharma Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Piramal Pharma Main Business Overview
11.18.5 Piramal Pharma Latest Developments
11.19 CPC Scientific
11.19.1 CPC Scientific Company Information
11.19.2 CPC Scientific Oligonucleotide CDMO Product Offered
11.19.3 CPC Scientific Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 CPC Scientific Main Business Overview
11.19.5 CPC Scientific Latest Developments
11.20 Eurogentec
11.20.1 Eurogentec Company Information
11.20.2 Eurogentec Oligonucleotide CDMO Product Offered
11.20.3 Eurogentec Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Eurogentec Main Business Overview
11.20.5 Eurogentec Latest Developments
11.21 Cambrex
11.21.1 Cambrex Company Information
11.21.2 Cambrex Oligonucleotide CDMO Product Offered
11.21.3 Cambrex Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Cambrex Main Business Overview
11.21.5 Cambrex Latest Developments
11.22 WuXi STA
11.22.1 WuXi STA Company Information
11.22.2 WuXi STA Oligonucleotide CDMO Product Offered
11.22.3 WuXi STA Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 WuXi STA Main Business Overview
11.22.5 WuXi STA Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
.
Table 1. Oligonucleotide CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Oligonucleotide CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of APIs and Intermediates
Table 4. Major Players ofFDF
Table 5. Oligonucleotide CDMO Market Size CAGR byType (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 7. Global Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Table 8. Oligonucleotide CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Table 11. Global Oligonucleotide CDMO Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Oligonucleotide CDMO Revenue Market Share by Player (2020-2025)
Table 13. Oligonucleotide CDMO Key Players Head office and Products Offered
Table 14. Oligonucleotide CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Oligonucleotide CDMO Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Table 19. Global Oligonucleotide CDMO Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Oligonucleotide CDMO Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Oligonucleotide CDMO Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Oligonucleotide CDMO Market Size Market Share by Country (2020-2025)
Table 23. Americas Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 24. Americas Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Table 25. Americas Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Table 27. APAC Oligonucleotide CDMO Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Table 29. APAC Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 30. APAC Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Oligonucleotide CDMO Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Oligonucleotide CDMO Market Size Market Share by Country (2020-2025)
Table 33. Europe Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 34. Europe Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Oligonucleotide CDMO Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide CDMO Market Size byType (2020-2025) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide CDMO Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Oligonucleotide CDMO
Table 39. Key Market Challenges & Risks of Oligonucleotide CDMO
Table 40. Key IndustryTrends of Oligonucleotide CDMO
Table 41. Global Oligonucleotide CDMO Market SizeForecast by Region (2026-2031) & ($ millions)
Table 42. Global Oligonucleotide CDMO Market Size Market ShareForecast by Region (2026-2031)
Table 43. Global Oligonucleotide CDMO Market SizeForecast byType (2026-2031) & ($ millions)
Table 44. Global Oligonucleotide CDMO Market SizeForecast by Application (2026-2031) & ($ millions)
Table 45. Agilent Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 46. Agilent Oligonucleotide CDMO Product Offered
Table 47. Agilent Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Agilent Main Business
Table 49. Agilent Latest Developments
Table 50. ST Pharm Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 51. ST Pharm Oligonucleotide CDMO Product Offered
Table 52. ST Pharm Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. ST Pharm Main Business
Table 54. ST Pharm Latest Developments
Table 55. Bachem Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 56. Bachem Oligonucleotide CDMO Product Offered
Table 57. Bachem Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Bachem Main Business
Table 59. Bachem Latest Developments
Table 60. BioSpring Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 61. BioSpring Oligonucleotide CDMO Product Offered
Table 62. BioSpring Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. BioSpring Main Business
Table 64. BioSpring Latest Developments
Table 65. Creative Biogene Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 66. Creative Biogene Oligonucleotide CDMO Product Offered
Table 67. Creative Biogene Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Creative Biogene Main Business
Table 69. Creative Biogene Latest Developments
Table 70. Sylentis Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 71. Sylentis Oligonucleotide CDMO Product Offered
Table 72. Sylentis Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Sylentis Main Business
Table 74. Sylentis Latest Developments
Table 75. Ajinomoto Bio-Pharma Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 76. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Offered
Table 77. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Ajinomoto Bio-Pharma Main Business
Table 79. Ajinomoto Bio-Pharma Latest Developments
Table 80. EUROAPI Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 81. EUROAPI Oligonucleotide CDMO Product Offered
Table 82. EUROAPI Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. EUROAPI Main Business
Table 84. EUROAPI Latest Developments
Table 85. Veliter Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 86. Veliter Oligonucleotide CDMO Product Offered
Table 87. Veliter Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Veliter Main Business
Table 89. Veliter Latest Developments
Table 90. PolyPeptide Group Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 91. PolyPeptide Group Oligonucleotide CDMO Product Offered
Table 92. PolyPeptide Group Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. PolyPeptide Group Main Business
Table 94. PolyPeptide Group Latest Developments
Table 95. CordenPharma Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 96. CordenPharma Oligonucleotide CDMO Product Offered
Table 97. CordenPharma Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. CordenPharma Main Business
Table 99. CordenPharma Latest Developments
Table 100.Thermofischer Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 101.Thermofischer Oligonucleotide CDMO Product Offered
Table 102.Thermofischer Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 103.Thermofischer Main Business
Table 104.Thermofischer Latest Developments
Table 105. Bio Basic Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 106. Bio Basic Oligonucleotide CDMO Product Offered
Table 107. Bio Basic Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 108. Bio Basic Main Business
Table 109. Bio Basic Latest Developments
Table 110. Genscript Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 111. Genscript Oligonucleotide CDMO Product Offered
Table 112. Genscript Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 113. Genscript Main Business
Table 114. Genscript Latest Developments
Table 115. Cytiva Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 116. Cytiva Oligonucleotide CDMO Product Offered
Table 117. Cytiva Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 118. Cytiva Main Business
Table 119. Cytiva Latest Developments
Table 120. ScinoPharm Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 121. ScinoPharm Oligonucleotide CDMO Product Offered
Table 122. ScinoPharm Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 123. ScinoPharm Main Business
Table 124. ScinoPharm Latest Developments
Table 125. CBL Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 126. CBL Oligonucleotide CDMO Product Offered
Table 127. CBL Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 128. CBL Main Business
Table 129. CBL Latest Developments
Table 130. Piramal Pharma Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 131. Piramal Pharma Oligonucleotide CDMO Product Offered
Table 132. Piramal Pharma Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 133. Piramal Pharma Main Business
Table 134. Piramal Pharma Latest Developments
Table 135. CPC Scientific Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 136. CPC Scientific Oligonucleotide CDMO Product Offered
Table 137. CPC Scientific Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 138. CPC Scientific Main Business
Table 139. CPC Scientific Latest Developments
Table 140. Eurogentec Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 141. Eurogentec Oligonucleotide CDMO Product Offered
Table 142. Eurogentec Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 143. Eurogentec Main Business
Table 144. Eurogentec Latest Developments
Table 145. Cambrex Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 146. Cambrex Oligonucleotide CDMO Product Offered
Table 147. Cambrex Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 148. Cambrex Main Business
Table 149. Cambrex Latest Developments
Table 150. WuXi STA Details, CompanyType, Oligonucleotide CDMO Area Served and Its Competitors
Table 151. WuXi STA Oligonucleotide CDMO Product Offered
Table 152. WuXi STA Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 153. WuXi STA Main Business
Table 154. WuXi STA Latest Developments
LIST OFFIGURES
Figure 1. Oligonucleotide CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide CDMO Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Oligonucleotide CDMO Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Oligonucleotide CDMO Sales Market Share by Country/Region (2024)
Figure 8. Oligonucleotide CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Oligonucleotide CDMO Market Size Market Share byType in 2024
Figure 10. Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies
Figure 11. Global Oligonucleotide CDMO Market: Pharmaceutical and Biotechnology Companies (2020-2025) & ($ millions)
Figure 12. Oligonucleotide CDMO in Research Institutes
Figure 13. Global Oligonucleotide CDMO Market: Research Institutes (2020-2025) & ($ millions)
Figure 14. Oligonucleotide CDMO in Others
Figure 15. Global Oligonucleotide CDMO Market: Others (2020-2025) & ($ millions)
Figure 16. Global Oligonucleotide CDMO Market Size Market Share by Application in 2024
Figure 17. Global Oligonucleotide CDMO Revenue Market Share by Player in 2024
Figure 18. Global Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Figure 19. Americas Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 20. APAC Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 21. Europe Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Oligonucleotide CDMO Market Size 2020-2025 ($ millions)
Figure 23. Americas Oligonucleotide CDMO Value Market Share by Country in 2024
Figure 24. United States Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Oligonucleotide CDMO Market Size Market Share by Region in 2024
Figure 29. APAC Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Figure 30. APAC Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Figure 31. China Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 35. India Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Oligonucleotide CDMO Market Size Market Share by Country in 2024
Figure 38. Europe Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Figure 39. Europe Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Figure 40. Germany Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 41.France Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Oligonucleotide CDMO Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Oligonucleotide CDMO Market Size Market Share byType (2020-2025)
Figure 47. Middle East & Africa Oligonucleotide CDMO Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 51.Turkey Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Oligonucleotide CDMO Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 54. APAC Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 55. Europe Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 57. United States Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 58. Canada Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 59. Mexico Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 60. Brazil Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 61. China Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 62. Japan Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 63. Korea Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 65. India Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 66. Australia Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 67. Germany Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 68.France Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 69. UK Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 70. Italy Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 71. Russia Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 72. Egypt Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 73. South Africa Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 74. Israel Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 75.Turkey Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
Figure 76. Global Oligonucleotide CDMO Market Size Market ShareForecast byType (2026-2031)
Figure 77. Global Oligonucleotide CDMO Market Size Market ShareForecast by Application (2026-2031)
Figure 78. GCC Countries Oligonucleotide CDMO Market Size 2026-2031 ($ millions)
